InMed Pharmaceuticals
13 hedge funds and large institutions have $266K invested in InMed Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
128% more capital invested
Capital invested by funds: $117K → $266K (+$149K)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
18% more funds holding
Funds holding: 11 → 13 (+2)
0.38% more ownership
Funds ownership: 0.26% → 0.64% (+0.38%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$187K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$54K |
| 3 |
Renaissance Technologies
New York
|
+$12.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.4K |
| 5 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$5.76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$81.6K |
| 2 |
VF
Virtu Financial
New York
|
-$14.8K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$4.73K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$54 |
| 5 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$21 |
INM Hedge Fund Activity: Q3 2024 in Review
13 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q3 2024, worth a combined $266K — up 128% from $117K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new INM positions and 4 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was AdvisorShares Investments, opening a new position worth an estimated $187K. The largest seller was Sabby Management, exiting entirely with an estimated $81.6K sold.
- 13 institutional investors held InMed Pharmaceuticals (INM) as of Q3 2024, up from 11 in Q2 2024.
- Funds reported $266K of InMed Pharmaceuticals stock for Q3 2024, up 128% quarter-over-quarter.
- 6 funds opened new InMed Pharmaceuticals positions in Q3 2024 and 4 closed out, a net change of +2 holders.
- The largest InMed Pharmaceuticals buyer in Q3 2024 was AdvisorShares Investments, an estimated $187K added.
- The largest InMed Pharmaceuticals seller in Q3 2024 was Sabby Management, an estimated $81.6K sold.
Based on aggregated 13F filings for Q3 2024.